Pre-Conditions for the Growth of Addiction

The United States faces a severe and multifaceted drug addiction crisis that has persisted for over two decades, with opioids serving as the primary driver of overdose mortality. Experts estimate that approximately 200,000 individuals in Ohio alone struggle with opioid addiction, reflecting a nationwide pattern of escalating substance use disorders affecting millions of Americans. While opioid overdoses have constituted the most visible crisis, the landscape has become increasingly complex, with rising trends in cocaine-related overdoses, benzodiazepine misuse, and alcohol use disorders complicating treatment and prevention efforts. The crisis extends beyond opioids to include methamphetamine, prescription painkillers, and other synthetic drugs that have become integrated into the broader substance abuse ecosystem.

The roots of the addiction crisis trace primarily to the aggressive marketing and promotion of prescription opioids by pharmaceutical manufacturers beginning in the 1990s, which created widespread access to highly addictive medications. The introduction and proliferation of illicit fentanyl—a synthetic opioid far more potent than heroin—exponentially accelerated overdose deaths beginning in the mid-2010s, with fentanyl involvement in overdose deaths skyrocketing from 503 cases in 2014 to 1,155 cases in 2015 in Ohio alone. Social factors including economic desperation, lack of access to mental health services, and the isolation created by the COVID-19 pandemic have further fueled addiction rates across all demographics. The drug supply itself has become increasingly contaminated and unpredictable, with illicit fentanyl and its analogs now present in cocaine, methamphetamine, and counterfeit prescription medications, making accidental overdoses far more common. Additionally, gaps in early intervention, limited availability of evidence-based treatment, and systemic barriers to addiction services have allowed the crisis to flourish without adequate public health response infrastructure.

Social and Economic Impacts

The opioid and broader drug addiction crisis has created unprecedented strain on healthcare systems across the United States, particularly in states like Ohio where overdose deaths have reached epidemic proportions. Emergency departments are overwhelmed with overdose cases requiring naloxone administration, intensive monitoring, and treatment for complications including respiratory failure, cardiac arrhythmias, and aspiration pneumonia. The crisis has diverted significant healthcare resources from other critical areas, including preventive care, chronic disease management, and routine surgical procedures, as hospitals dedicate emergency capacity to overdose emergencies. Addiction treatment facilities face overwhelming demand that exceeds available capacity, creating months-long waiting lists for evidence-based treatment programs such as medication-assisted treatment (MAT) with methadone or buprenorphine. Additionally, the healthcare system bears substantial costs for treating overdose-related complications, infectious diseases transmitted through injection drug use (including hepatitis C and HIV), and long-term disabilities resulting from non-fatal overdoses, straining both hospital budgets and public health funding.

Beyond healthcare, the drug crisis devastates public safety systems and economic productivity across affected communities. Law enforcement agencies spend enormous resources on drug-related arrests, investigations, and prosecutions, diverting personnel and funding from other public safety priorities, while the criminal justice system processes hundreds of thousands of drug-related cases annually that burden courts and correctional facilities. The epidemic creates direct economic losses through reduced workforce participation, disability payments, and lost productive capacity—individuals struggling with addiction experience unemployment rates far exceeding national averages and are often unable to maintain stable employment. Families are fractured as parents, children, and breadwinners succumb to overdose or face incarceration, creating generational trauma and increasing demand for child protective services, foster care, and social support systems. Communities experiencing high overdose rates also suffer from reduced property values, increased crime, business disinvestment, and deteriorating neighborhood conditions, creating cycles of poverty and despair that make recovery and prevention efforts more difficult.

Federal Countermeasures

Expanded Access to Medication-Assisted Treatment and Buprenorphine Distribution

The federal government has prioritized expanding access to evidence-based medication-assisted treatment (MAT) by removing regulatory barriers that previously limited buprenorphine prescribing in office-based settings. This initiative allows qualified healthcare providers to prescribe buprenorphine—a partial opioid agonist with lower abuse potential and overdose risk compared to methadone—directly in clinical offices rather than requiring patients to attend specialized opioid treatment programs daily. The approach has significantly expanded treatment capacity by enabling primary care physicians, nurse practitioners, and physician assistants to provide addiction treatment, reducing wait times and increasing accessibility for rural and underserved populations. Federal funding has supported training programs for healthcare providers to prescribe buprenorphine safely and effectively, while insurance coverage expansions have reduced cost barriers for patients seeking treatment. Research indicates that buprenorphine-based MAT reduces illicit opioid use by 50-70% and decreases overdose risk substantially, making it a critical tool in reducing opioid-related mortality.

National Naloxone Distribution and Overdose Reversal Programs

The federal government has championed widespread distribution of naloxone (Narcan), an opioid antagonist that rapidly reverses opioid overdoses within 2-3 minutes of administration, through multiple channels including community organizations, harm reduction programs, emergency services, and pharmacies. This initiative removes prior restrictions that limited naloxone availability, allowing non-prescription distribution to at-risk individuals, family members, and bystanders who may encounter overdoses. Federal grants support community-based naloxone distribution programs that have distributed nearly 90,000 naloxone kits in Ohio alone since 2014, with approximately 11,000 overdose reversals documented through these programs. The strategy recognizes that naloxone distribution saves lives immediately by providing a reversible treatment for overdose, buying critical time for emergency medical services to arrive and provide further care. By democratizing access to naloxone, the federal approach empowers communities and individuals to prevent fatal overdoses regardless of formal healthcare access.

Data-Driven Surveillance and Rapid Response Networks

Federal agencies including the CDC have established sophisticated surveillance systems that track overdose mortality in real-time through rapid release provisional data systems, allowing jurisdictions to identify emerging trends and respond quickly to spikes in overdose deaths. These surveillance networks identify new drug threats, unusual patterns in overdose causes (such as sudden increases in specific drug combinations or contamination events), and geographic hotspots requiring targeted intervention. The rapid data release system provides preliminary mortality data with only 4-month lags rather than the traditional 12-18 month delays, enabling public health agencies to implement emergency response measures quickly when overdose rates spike. Federal funding supports community epidemiology working groups that combine law enforcement, treatment providers, and public health professionals to analyze local drug patterns and coordinate responses. This data-driven approach enables evidence-based resource allocation and allows jurisdictions to pivot strategies quickly when new threats emerge, such as fentanyl contamination or novel synthetic opioids.

Comprehensive Opioid Recovery Centers and Integrated Service Models

The federal government has invested in establishing comprehensive opioid recovery centers that provide integrated, evidence-based treatment combining medication-assisted treatment, behavioral health services, peer support, housing assistance, and employment support within coordinated service systems. These centers adopt a “low-barrier” approach that minimizes administrative requirements and accepts patients regardless of insurance status, criminal justice involvement, or previous treatment failures. The integrated model recognizes that successful recovery requires addressing not only opioid use but also co-occurring mental health conditions, housing instability, unemployment, and social isolation—factors that typically drive relapse and overdose. Federal grant programs support hiring of peer recovery specialists—individuals with lived experience of addiction and recovery—who provide mentorship, accountability, and hope to patients navigating treatment. Research demonstrates that comprehensive center-based approaches reduce overdose mortality by 30-50% compared to medication-only or counseling-only interventions, making them among the most effective federal interventions.

Criminal Justice Reform and Diversion Programs for Non-Violent Drug Offenders

The federal government has funded and promoted drug courts, diversion programs, and criminal justice reforms that redirect individuals with substance use disorders away from incarceration and into treatment, recognizing that incarceration without treatment perpetuates cycles of addiction and relapse. These programs allow individuals charged with drug-related offenses to participate in intensive treatment, supervision, and rehabilitation programs as alternatives to prosecution and incarceration. Federal support for these initiatives includes funding for dedicated drug court judges, treatment coordinators, and regular monitoring to ensure accountability and therapeutic progress. Studies show that drug court participants experience 35-80% reductions in recidivism compared to traditionally prosecuted individuals, while also achieving significant reductions in drug use and improved employment and housing stability. By treating addiction as a public health problem rather than a criminal justice issue, this federal approach simultaneously reduces incarceration burden and improves individual and community health outcomes.

Ohio Case – The Numbers Speak for Themselves

Ohio has experienced a remarkable turnaround in overdose mortality after decades of escalating opioid-related deaths, providing a compelling case study of how targeted interventions can reverse even severe epidemics, as reflected in drugs in ohio data. The state’s opioid addiction crisis reached catastrophic proportions during the mid-2010s, with Montgomery County earning the grim distinction of being designated the overdose capital of the United States—experiencing 365 overdose deaths in the first five months of 2017 alone, nearly equaling the entire 2016 annual count of 371 deaths. Ohio’s total unintentional drug overdose deaths have declined dramatically: from 4,915 deaths in 2022 to 4,452 deaths in 2023—a 9% decrease that substantially outpaced the national 2% decline. Even more remarkably, preliminary data suggests Ohio achieved approximately a 35% reduction in overdose deaths in 2024, representing the most significant one-year decline since 2019, with some communities reporting 40-50% annual reductions in fatal overdoses.

Illicit fentanyl and its analogs remain the dominant cause of overdose mortality in Ohio, involved in 78% of unintentional drug overdose deaths in 2023, though typically in combination with other substances such as cocaine, benzodiazepines, or heroin. Notably, deaths involving natural and semi-synthetic opioids (including prescription medications like oxycodone) decreased by 20% from 2022 to 2023, suggesting that efforts to reduce inappropriate opioid prescribing are yielding results. However, emerging concerns include rising cocaine-related overdose deaths (up 7% from 2022 to 2023), increased benzodiazepine-related deaths (up 4%), and persistent methamphetamine involvement in overdose cases, indicating that Ohio’s drug crisis is evolving and diversifying beyond solely opioid-focused threats. The dramatic recent decline in total overdose deaths represents genuine lives saved—each percentage point reduction translates to dozens of Ohioans who survived overdoses and have opportunities to recover.

Ohio State Programs

Project DAWN (Deaths Avoided With Naloxone)

Project DAWN is Ohio’s primary naloxone distribution program that provides free naloxone kits to individuals at risk of opioid overdose, family members, and community members who may encounter overdose emergencies. Since its inception in 2014, the program has distributed nearly 90,000 naloxone kits through community organizations, harm reduction agencies, and healthcare providers, with approximately 11,000 overdose reversals documented through this program—meaning 11,000 lives were directly saved by the availability of naloxone. Project DAWN combines immediate overdose response capacity with opportunities for engagement in treatment and recovery services, as each naloxone distribution includes educational materials about addiction resources and treatment options, creating touchpoints for connecting individuals to longer-term care.

Integrated Naloxone Access and Infrastructure Program

The Ohio Department of Health has implemented the Integrated Naloxone Access and Infrastructure (INAI) program utilizing funds from Ohio Mental Health and Addiction Services to establish 118 naloxone distribution strategies across 37 community agencies and organizations. This program strategically distributes naloxone to high-risk populations by placing it in community agencies serving vulnerable populations, jails and correctional facilities, recovery housing, hospital emergency departments, homeless outreach programs, mail-based distribution, drug courts, and syringe access programs. The distributed, comprehensive approach ensures that naloxone reaches individuals across multiple touchpoints in their lives—whether in healthcare settings, criminal justice systems, housing programs, or community organizations—maximizing the likelihood that naloxone will be available at the moment of overdose crisis. By embedding naloxone distribution across diverse institutional settings, Ohio has created a statewide infrastructure that normalizes overdose reversal and treats it as a fundamental public health tool rather than a specialized emergency measure.

Violence and Injury Prevention Services (VIPS) Overdose Prevention and Treatment Coordination

The Ohio Department of Health’s Violence and Injury Prevention Services (VIPS) coordinates comprehensive statewide overdose prevention, response, and treatment strategies that integrate surveillance, harm reduction, treatment access, and community engagement. VIPS allocates state funding for naloxone distribution, supports community epidemiology efforts to identify emerging drug threats and overdose patterns, and coordinates with treatment providers and emergency services to ensure rapid response to overdose surges. The program’s integrated approach addresses overdose prevention through multiple simultaneous strategies—immediate response through naloxone availability, medium-term treatment through expanded access to medication-assisted treatment and behavioral health services, and long-term prevention through substance abuse education and early intervention programs in schools and community settings. VIPS’ coordinating function ensures that Ohio’s diverse overdose prevention initiatives work together coherently rather than in isolation, creating synergistic effects that amplify impact beyond what individual programs could achieve separately.

Approaches in Neighboring Regions

Ohio’s three geographically closest U.S. states—Pennsylvania, West Virginia, and Kentucky—have each developed distinct but complementary strategies for addressing opioid and drug overdose crises affecting their populations.

• Pennsylvania: Pennsylvania has implemented a statewide Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP) that provides coordinated funding and strategic direction for evidence-based interventions across the state’s 67 counties, ensuring consistent access to medication-assisted treatment, naloxone distribution, and recovery support services regardless of geographic location. The program emphasizes workforce development by training community health workers and peer recovery specialists to expand treatment capacity beyond traditional clinical settings, creating employment opportunities while simultaneously improving access to culturally competent care in underserved communities. Pennsylvania’s approach includes robust data sharing between emergency departments, law enforcement, and public health agencies that enables rapid identification of overdose surges, contaminated drug batches, and emerging drug threats, allowing for quick coordinated response interventions. The state has also established community coalitions in high-burden counties that bring together law enforcement, treatment providers, healthcare systems, and community organizations to implement locally-tailored strategies addressing specific drug threats and population needs identified through data analysis.
• West Virginia: West Virginia has prioritized expansion of medication-assisted treatment capacity through a combination of federal grant funding and state investment in training healthcare providers and establishing new treatment facilities in rural and underserved areas where treatment was previously unavailable or required travel of 50+ miles. The state has implemented comprehensive criminal justice reform that includes drug courts, pretrial diversion programs, and treatment-focused incarceration alternatives that recognize addiction as a health issue rather than primarily a criminal justice problem, significantly reducing incarceration while improving treatment engagement and recovery outcomes. West Virginia’s harm reduction programs include syringe services programs, supervised injection facilities in clinical settings, and community-based harm reduction that acknowledge that meeting people where they are—without judgment and without requiring abstinence as a precondition—creates pathways to eventual treatment engagement and recovery. The state has also established peer support networks and recovery community organizations that provide ongoing support, mentorship, and social connection for individuals in recovery, addressing the isolation and social disconnection that often precipitate relapse.
• Kentucky: Kentucky has developed a coordinated system of Regional Prevention and Treatment Hubs that consolidate overdose prevention, emergency response, treatment initiation, and recovery support services into integrated facilities accessible to communities across the state, reducing fragmentation and creating “one-stop” access to comprehensive services. The hub system emphasizes rapid access to medication-assisted treatment by eliminating waiting lists, allowing same-day or next-day treatment initiation for individuals presenting with acute overdose crisis or motivated engagement in treatment services. Kentucky has implemented emergency department screening and brief intervention protocols requiring all patients presenting to emergency departments with overdose or suspected opioid use to receive assessment, naloxone prescription, treatment referral, and follow-up contact, converting emergency visits into treatment engagement opportunities. The state’s recovery-oriented systems of care approach emphasizes long-term community reintegration, peer support, employment assistance, and housing stability as essential components of recovery equal in importance to acute medical treatment and medication-assisted therapy.

Is It Possible to Stop the Crisis? Looking to the Future

Approaches with Strong Potential for Effectiveness

• Investment in Comprehensive Treatment Infrastructure and Medication-Assisted Treatment Expansion: Expanding capacity for evidence-based medication-assisted treatment (methadone, buprenorphine, naltrexone), eliminating treatment waitlists, and ensuring insurance coverage removes the most significant barrier to recovery for opioid-dependent individuals. Research demonstrates that MAT reduces illicit opioid use by 50-70% and decreases overdose risk substantially, with effects sustained over years for individuals remaining engaged in treatment. Creating diverse treatment settings from primary care offices to specialized addiction centers ensures accessibility across geography and socioeconomic status. Investment in treatment infrastructure represents a health system transformation that directly saves lives while enabling long-term recovery and social reintegration.
• Early Intervention and Prevention Programs Targeting Youth and High-Risk Populations: Evidence-based school prevention curricula, community education about addiction risk factors, screening in healthcare settings, and early intervention for individuals showing signs of substance misuse prevent addiction development and identify individuals for treatment before severe dependence develops. Early intervention in adolescence addresses addiction vulnerabilities during critical brain development periods when intervention has maximal preventive impact. School-based and community programs that provide skills-building, mentorship, and prosocial opportunities create protective factors offsetting biological and environmental risk factors. Screening in healthcare settings identifies individuals with substance use before overdose occurs, creating opportunities for prevention and early treatment engagement before crisis intervention becomes necessary.
• Integrated Care Models Combining Medical Treatment, Mental Health Services, and Social Support: Addressing co-occurring mental health conditions (depression, anxiety, PTSD, bipolar disorder) that frequently accompany and contribute to substance use disorders requires integrated treatment that doesn’t compartmentalize addiction from psychiatric care. Providing housing stability, employment support, family services, and peer mentorship addresses the social determinants and risk factors that maintain addiction and precipitate relapse even among individuals receiving excellent medical and psychiatric treatment. Comprehensive care models that address the whole person rather than isolated substance use have demonstrated superior outcomes in research across multiple treatment settings and populations. Integration across healthcare, social services, housing, and employment systems creates coherent pathways to sustainable recovery and long-term wellbeing.
• Data-Driven Public Health Response with Rapid Surveillance and Flexible Resource Allocation: Establishing real-time surveillance systems identifying emerging overdose surges, new drug threats, and contamination events allows public health agencies to respond rapidly with targeted interventions before problems become widespread. Flexible funding mechanisms that allow reallocation of resources to areas experiencing sudden increases in overdose deaths or exposure to novel synthetic opioids ensure efficient use of limited resources and rapid response capacity. Community epidemiology approaches integrating law enforcement, treatment providers, and public health professionals create shared understanding of local drug markets and threats, enabling coordinated intervention across traditionally siloed systems. Data-driven approaches replace one-size-fits-all strategies with tailored interventions matching specific local drug threat profiles and population characteristics.
• Decriminalization and Criminal Justice Reform Coupled with Treatment Access: Treating drug use primarily as a public health rather than criminal justice issue through drug courts, diversion programs, and treatment-focused responses reduces incarceration while improving treatment engagement and recovery outcomes. Removing criminal penalties that function as barriers to treatment engagement (such as felony charges preventing employment, housing access, and social reintegration) allows individuals to focus on recovery without compounding obstacles. Criminal justice reform frees law enforcement resources for more serious crimes while reducing burden on courts and correctional systems. Evidence from multiple jurisdictions demonstrates that decriminalization coupled with treatment access (not decriminalization alone) reduces overdose mortality and improves community safety outcomes compared to traditional enforcement approaches.

Approaches with Limited Effectiveness or Significant Limitations

• Enforcement-Only and “War on Drugs” Approaches Without Treatment Access: Decades of research demonstrate that enforcement and incarceration without accompanying treatment access fail to reduce drug use, overdose mortality, or addiction prevalence, instead creating incarceration cycles that destabilize individuals and families while generating minimal public health benefit. Incarceration without treatment perpetuates addiction by housing individuals with untreated addictions in environments offering unlimited access to drugs while disrupting employment, housing, and social connections essential to recovery. Enforcement approaches create criminal records that become lifelong barriers to employment and housing, functioning as secondary penalties that increase overdose risk by preventing economic stability and social integration. The enormous expense of enforcement and incarceration (estimated at $50,000+ annually per incarcerated individual) diverts resources from evidence-based treatment that costs a fraction of incarceration while producing substantially better outcomes.
• Isolation-Based Treatment Without Peer Support and Community Integration: Treatment models emphasizing isolation from society, severing existing social connections, and providing minimal peer support show high relapse rates because they fail to address the profound social isolation and disconnection that characterize addiction. Individuals in recovery require ongoing social connection, purpose, meaningful relationships, and integration into non-drug-using communities—isolation during and after treatment actually increases relapse risk by intensifying the loneliness and disconnection that addiction addressed through community belonging. Long-term abstinence-only models without medication support show lower success rates than medication-assisted treatment models combining medication with peer support and community integration. Creating sustainable recovery requires building or rebuilding social supports, employment, housing stability, and community belonging—objectives impossible without active community engagement and peer connection.
• Treatment Without Aftercare and Long-Term Support Systems: Treatment completion without sustained aftercare, peer support, mental health services, housing assistance, and employment support results in high relapse rates because individuals re-enter environments and circumstances that originally precipitated addiction without new coping tools or changed circumstances. Addiction recovery research demonstrates that transition periods following treatment completion represent peak relapse risk, making aftercare not supplementary but essential to treatment success. Treatment models concluding with program completion rather than transitioning into extended recovery support communities fail to maintain the protective factors and social connection necessary for sustained recovery. Programs emphasizing short-term acute treatment without long-term community reintegration essentially ensure that most individuals relapse within months of treatment completion, negating treatment benefits and perpetuating addiction cycles.
• Medication Prescription Restriction Without Alternative Opioid Access or Addiction Treatment: While reducing inappropriate opioid prescribing is important, abruptly restricting legitimate opioid access without providing addiction treatment alternatives creates suffering for individuals with chronic pain while driving opioid-dependent individuals to illicit markets offering far more dangerous substances (heroin, fentanyl) with contamination risk. Prescription restriction policies without accompanying expansion of addiction treatment capacity transfer individuals from relatively safe pharmaceutical supply chains to unregulated illicit markets where contamination and overdose risk are exponentially higher. Long-term opioid therapy for chronic non-cancer pain remains evidence-based treatment for carefully selected individuals, and eliminating all opioid prescribing harms patients while failing to prevent addiction for vulnerable individuals who simply access opioids through illicit channels. Evidence-based approaches balance reducing inappropriate opioid prescribing with maintaining access for individuals with legitimate medical needs while simultaneously expanding addiction treatment capacity.
• Educational Campaigns and Awareness Alone Without Treatment Infrastructure: Public awareness campaigns about overdose risk and addiction dangers have minimal impact on addiction prevalence or overdose mortality without simultaneous expansion of accessible treatment. Individuals struggling with addiction typically are painfully aware of the dangers and harms of their substance use—awareness rarely changes behavior when addiction has developed because addiction involves neurobiological changes affecting reward processing and impulse control beyond conscious volition. Educational campaigns prove most effective when coupled with messages about specific accessible treatment resources and pathways to engagement, converting awareness into action. Education unaccompanied by treatment access essentially blames individuals for addiction without providing tools for recovery, potentially increasing shame and reducing treatment-seeking rather than improving outcomes.

Conclusions and Recommendations

The drug crisis affecting the United States represents one of the most significant public health challenges of our time, demanding recognition that addiction is fundamentally a medical and public health issue requiring compassionate, evidence-based response rather than moral judgment or enforcement-only approaches. Ohio’s dramatic recent decline in overdose mortality—from 4,915 deaths in 2022 to 4,452 in 2023 and an estimated 35% reduction in 2024—demonstrates conclusively that the opioid epidemic is not inevitable or irreversible; strategic, comprehensive interventions combining medication-assisted treatment expansion, naloxone availability, data-driven surveillance, criminal justice reform, and integration of medical and social services can turn even severe epidemics around. The evidence overwhelmingly demonstrates that successful strategies share common elements: they are grounded in reliable epidemiological data identifying specific local threats and population needs; they employ evidence-based interventions with proven efficacy demonstrated in rigorous research; they operate with long-term commitment recognizing that sustainable addiction recovery requires years of support rather than brief acute intervention; and they treat individuals experiencing addiction with dignity and respect while providing concrete pathways to recovery and social reintegration.

Each state faces distinct challenges reflecting unique population characteristics, drug market dynamics, geography, and existing infrastructure, necessitating tailored strategies rather than uniform national approaches applied identically across diverse contexts. However, the principles underlying successful responses transcend geographic boundaries: investment in accessible, evidence-based treatment; widespread availability of overdose reversal medications; coordination across healthcare, law enforcement, and social service systems; and commitment to data-driven decision-making rather than ideology-driven policies. The path forward requires sustained public health responsibility at federal, state, and local levels—sustained funding not subject to political cycles, workforce development creating career pathways for addiction treatment specialists and peer recovery professionals, infrastructure investment in treatment facilities and recovery support services, and integration of addiction medicine into mainstream healthcare as a standard specialty rather than marginalized afterthought. Success requires open dialogue acknowledging that no single intervention suffices—medication-assisted treatment, peer support, housing, employment, education, and enforcement all play necessary roles within comprehensive systems of care. Most critically, sustained success demands genuine long-term support for individuals in recovery, recognizing that recovery is a process spanning years and decades rather than weeks or months, requiring ongoing access to medication, mental health services, peer communities, and social connection. Ohio’s progress provides hope and a roadmap for other states: the crisis can be reversed through strategic investment, evidence-based practice, interagency cooperation, and unwavering commitment to treating addiction as the medical emergency it represents, worthy of the same comprehensive, sophisticated response we provide for other life-threatening conditions.